Back to search page

TRES20200921001

COVID-19: Accredited laboratory or Contract Research Organisation (CRO) required to certificate the virucidal capacity against coronavirus SARS-CoV-2 of a 3D printing filament and printed objects according to ISO 21702 standards.

TECHNOLOGY PROFILE   REQUEST   ADD TO FAVOURITES
PRINT

 

ABSTRACT

A Spanish company specialized in the development and production of 3D printing filaments has created a TPU-based (Thermoplastic Polyurethane) filament with antiviral properties. They require an accredited laboratory to certify the virucidal capacity against SARS-CoV-2 of the filament and printed objects. The laboratory will issue an official certificate for the conformity assessment of the ISO 21702 standards under a technical services agreement.


FULL DESCRIPTION

This is a Spanish dynamic and young company (funded in 2019), which is made up of a team of professional staff with long and proven experience in additive manufacturing and previous entrepreneurial projects in this industry. The company is located in Alicante, an area that is becoming a pole of digital innovation due to the emergence of many private initiatives and the support of local and regional administrations.

The firm is a technological and innovative company that develops, produces and markets technical 3D filaments and granulates for the additive manufacturing sector. The production process is all done in Spain, at the company’s own premises. It allows full control of the entire production process and to and quickly incorporate the latest technologic developments with the aim of offering the highest product quality and standards.

The company started its commercial activity in 2019 putting in the market a range of aromatic filaments (up to 10 fragrances). New product developments were put in the market soon afterwards: 1 filament 100% made from recycled fishing nets, 1 mosquito repellent filament and 1 antibacterial (medical use) filament. These products are all patented and produced with the highest quality TPU in the market.

The experience gained in developing the antibacterial filament enabled the company to participate in medical collaborative research projects aimed at developing 3D printed implants, an involvement that rendered the company contacts in the health care sector and valuable know-how.

With the irruption of the COVID-19 pandemic, the company undertook the project to bring to the market a 3D TPU-based flexible filament capable of neutralizing the growth or the proliferation of SARS-CoV-2. This product is fully developed and ready to be sold. It is based on a biocidal (antibacterial and viricidal) formulation, which incorporated in the filament does not alter the printing process and does not damage the printed objects or its material and plastic properties. The final product is not harmful for the environment or for organisms with which it comes into contact.

In vitro test already carried out by independent laboratories shows the plastic objects printed with this filament prevents the deposit and growth of pathogens such as Escherichia coli, Legionella, Pseudomonas, Salmonella, Listeria monocytogenes, Staphylococcus aureus, Aspergillus niger, Trichophyton mentagrophytes, Campylobacter jejuni, Herpes simplex, Norovirus, Rhinovirus or Avian influenza.

In order to market the product with an official ISO certification, the Spanish company requires an accredited public or private laboratory able to conduct the clinical microbiological test aimed at measuring the SARS-CoV-2 antiviral activity of the 3D filament and the printed objects according to the ISO 21702: 2019 standards.

The contract will be formalised through a technical services agreement.


Partner expertise sought:

- Type of partner sought: The potential partner should be a laboratory or a Contract Research Organization (CRO), public or private, accredited by a National Accreditation Body (NAB) or member of European Accreditation (EA). The partner sought has to be able to issue official certificates and conduct conformity assessment according to the ISO 21702: 2019 standards.
- Specific area of activity of the partner: Under a technical service agreement, the contracted laboratory will conduct a test to certificate the antiviral capacity of the company’s filament against SARS-CoV-2.


Development Stage:

Already on the market


IPR:

Patent(s) applied for but not yet granted,Patents granted,Trade Marks,Copyright

Sign-in or create an account

To express an interest in this profile, you must first sign in or create a new account.

If you already have an account, sign in here

Not got an account yet, sign up here

KEY INFORMATION

Country of origin
SPAIN
Profile date
02/10/2020
Deadline
03/10/2021

PARTNERSHIP(S) SOUGHT

Services agreement

CLASSIFICATIONS

INDUSTRY SECTORS
Life Sciences \ Measurement, Testing & Standards \ Biosciences and Health \ Drug Discovery and Drug Development \ Medical Devices
TECHNOLOGY KEYWORDS
BIOLOGICAL SCIENCES / Medicine, Human Health / Virus, Virology/Antibiotics/Bacteriology / BIOLOGICAL SCIENCES / Biology / Biotechnology / In vitro Testing, Trials / MEASUREMENTS AND STANDARDS / Standards / Technical Standards
COMMERCIAL KEYWORDS
none...
MARKET KEYWORDS
GENETIC ENGINEERING/MOLECULAR BIOLOGY / In vitro Testing, Trials

FIND OUT MORE

Contact Enterprise Europe Network Scotland by email at info@enterprise-europe-scotland.com, quoting reference number TRES20200921001